• OFID 2018:5 (Suppl 1) • Poster Abstracts frequently require greater than 1 year of therapy. Although the toxicity profile of fluconazole has been evaluated in clinical trials, there is a paucity of data regarding the tolerability of this agent with long-term therapy.
Background. Patients with coccidioidal meningitis require life-long antifungal therapy and cumulative toxicity from these agents may occur. Isavuconazole is the newest triazole antifungal and has demonstrated a lower toxicity profile than voriconazole and may represent a useful therapy in meningitis, although no data regarding efficacy in coccidioidal meningitis has yet been presented.
Methods. We conducted a retrospective analysis of all coccidioidal meningitis patients treated at our centers. Data abstracted included demographic and clinical information, results of laboratory and radiographic studies, serologic results, and outcomes. Responses to therapy were measured using a previously validated scoring system used in clinical trials of coccidioidal meningitis (MSG Coccidioidomycosis Scoring System).
Results. Nine patients met criteria for inclusion. Seven of nine were previously treated with voriconazole and transitioned to isavuconazole following: photodermatitis, five patients; transaminitis and photodermatitis one patient; failure of therapy, one patient. Two other patients failed fluconazole therapy and were transitioned to isavuconazole as salvage therapy. All patients transitioned to isavuconazole had a complete response to therapy five patients; or were deemed partial response (stable disease), four patients.
Conclusion. Isavuconazole therapy resulted in symptomatic and laboratory improvement in five of nine patients. The remaining patients exhibited clinical resolution of symptoms or continued with stable disease following adverse reactions to prior alternative triazole therapy. Isavuconazole may be a useful addition to the therapeutic choices currently available for coccidioidal meningitis.
Disclosures. All authors: No reported disclosures. Background. Differentiating between localized and disseminated cryptococcal disease is key to the management of this infection, since induction therapy with amphotericin B and flucytosine is warranted in the latter. We compared mortality in disseminated Cryptococcus with non-central nervous system (CNS) involvement, with those with CNS involvement and localized pulmonary disease.
Outcomes in Patients With
Methods. Demographics, predisposing factors, presentation, laboratory values, treatment and outcome data were collected retrospectively on patients hospitalized at an academic tertiary-care hospital for cryptococcal infection from 2002 to 2017. Outcomes were compared between three patient groups based on extra-pulmonary and CNS involvement. Survival analysis was performed using univariate and multivariate Cox Regression with censoring at 90 days.
Results. Of 312 patients identified, 63 (20%) had pulmonary, 154 (49.2%) CNS and 95 (30.4%) had disseminated non-CNS disease. At day 90, 38 (40%) from the disseminated non-CNC group had died, compared with 37 (24%) in the CNS disease and 13 (20.6%) in the pulmonary groups. After adjusting for age ≥55 years, organ transplant, end-stage liver disease (ESLD) and AIDS, 90-day mortality risk was higher in the disseminated non-CNS group compared with the pulmonary (HR 2.97 [95% CI 1.55, 5.7] ; P = 0.001) and the CNS disease group (1.84 [1.16, 2.93]; P = 0.009) (Figure 1 ). Median [IQR] time to diagnosis was 10 [4, 19] days and not significantly different between groups (P = 0.752). Induction therapy for ≥2 weeks was more common in the CNS disease (64.3%) that in the pulmonary (33.3%) or disseminated non-CNS disease group (38.7%) (P = 0.01). Median duration of azole therapy in days was longer (315 [61, 750] Background. Cryptococcal disease (CD) often has an insidious presentation and can be difficult to recognize. However, delayed diagnosis can lead to increased morbidity and mortality.
Methods. To estimate the potential number of missed opportunities for CD diagnosis we utilized the Healthcare Cost and Utilization Project State Inpatient Database from the Agency for Healthcare Research and Quality for the state of Florida from 2005 to 2014. We defined a missed opportunity as an admission with a new diagnosis of CD preceded by a hospitalization in the prior 90-days coded for an infection, respiratory, or central nervous system condition suggestive of CD. We performed descriptive statistics including mortality in each exposure group within one year after CD diagnosis.
Results. We identified 1,622 CD-related hospital discharges in Florida from April 2005 to December 2014. The median age of CD patients was 47 years, 30.6% were female, and 55.5% were coded for HIV/AIDS. Of those, 850/1,622 (52.4%) had meningitis. Five hundred sixty (34.5%) had a prior hospitalization within 90 days before the first hospitalization coded for CD. Of those, 50.9% (285/560) had a potentially missed opportunity to diagnose CD of whom 138/285 (48.4%) were HIV-positive. Of 560 patients, 49 (8.7%) were coded during a prior hospitalization with CNS conditions, 162 (28.9%) with respiratory conditions and 74 (13.2%) coded with both CNS and respiratory conditions. Patients who were coded for CNS diagnoses in a prior admission were more likely to be diagnosed with CD meningitis (P < 0.001). Of those with prior respiratory conditions 29/218 (13.3%) died during the CD admission, and 12.5% of those with prior CNS conditions died during the CD admission. Of those without a prior admission in the past 90 days, 110/1,062 (10.4%) died during the CD admission.
Conclusion. Cryptococcosis is a deadly disease that affects patients with both competent and incompetent immune systems. Missed opportunities to diagnose CD are relatively commonmand may contribute to worse outcomes.
Disclosures. All authors: No reported disclosures. , October 4, 2018: 12:30 PM Background. Histoplasmosis is considered uncommon in India, and the diagnosis usually depends on invasive tissue sampling. The histoplasma urinary antigen assay is a non-invasive test that has been recently introduced in India.
Clinical Features of Proven and Probable Cases of Histoplasmosis and the
Methods. This was a single-centre retrospective study done from January 2013 till February 2018. Case records of patients with proven (confirmed by demonstrating intra-cellular yeast like organisms on histopathology or culture) and probable (presence of antigenuria-done by IMMY Alpha Histoplasma enzyme immunoassay) histoplasmosis were analysed.
Results. A total of 37 patients (18 proven and 19 probable) with mean age of 51.59 ± 11.17 years were studied. Diabetes was the most common co-morbidity (15 patients) followed by HIV (6), whereas no co-morbidity was found in 10 patients. Adrenals (29%), lungs (27%), lymph nodes (27%), and skin and oral mucosa (24.3%) were the most common organs involved (Figure 1 ). Anti-tubercular therapy based on granulomatous inflammation was given to 10 patients prior to the diagnosis. Raised GGTP and ALP (54%) and hyperglobulinemia (40%) were the common laboratory features. Most patients (83.7%) came from endemic areas (North-Eastern states, West Bengal, and Bangladesh) whereas all six cases from non-endemic areas were classified as probable (Figure 2 ). All-cause mortality rate was 10.8%, with 27 cases (72.9%) showing improvement at a median follow-up of 6 months. Comparison of proven and probable cases revealed that the following features were significantly higher in theprobable group: female sex (P = 0.001), coming from nonendemic areas (P = 0.009), requiring in-patient care (P = 0.001), leucocytosis (P = 0.043), absence of skin and oral mucosal findings (P = 0.002), simultaneous alternate diagnosis (P = 0.039), and death (P = 0.039).
Conclusion. This study emphasises that histoplasmosis is an under recognised entity in India. Histoplasma antigenuria does help in making the diagnosis easily and needs to be more extensively utilized by clinicians. However, it can yield false-positive results in patients belonging to nonendemic areas and lacking typical clinical features of histoplasmosis. Further studies are needed to determine the utility of the antigen test in Indian settings. 
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